Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...

A shortage of weight-loss drugs such as the newly released Ozempic rival Zepbound, is forcing desperate customers to drive as ...

Eli Lilly’s (NYSE:LLY) weight-loss drug Zepbound (tirzepatide) will remain in short supply through April-end amid increased ...

Amid a flurry of weight loss readouts, a fresh-on-the-scene startup has come out with Phase I results showing weight loss at day 36 on par with or better than competitors, with few gastrointestinal ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate hearing today about the prices of Ozempic and Wegovy.

With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

Preclinical research in mice found the pairing of azelaprag with Eli Lilly weight management drug Zepbound led to greater weight loss than Zepbound alone. Furthermore, BioAge reported the drug ...

BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the ...

BioAge's lead drug, azelaprag, is being developed to treat obesity, in combination with GLP-1 agonists such as Eli Lilly's Zepbound and Novo Nordisk's Wegovy. Affiliates of existing investor ...